Growth Metrics

Fulgent Genetics (FLGT) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Fulgent Genetics (FLGT) over the last 10 years, with Q3 2025 value amounting to -$6.6 million.

  • Fulgent Genetics' Net Income towards Common Stockholders rose 5488.8% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.0 million, marking a year-over-year increase of 7394.48%. This contributed to the annual value of -$42.7 million for FY2024, which is 7455.21% up from last year.
  • As of Q3 2025, Fulgent Genetics' Net Income towards Common Stockholders stood at -$6.6 million, which was up 5488.8% from -$19.0 million recorded in Q2 2025.
  • Fulgent Genetics' Net Income towards Common Stockholders' 5-year high stood at $200.7 million during Q1 2021, with a 5-year trough of -$128.1 million in Q4 2023.
  • Its 5-year average for Net Income towards Common Stockholders is $20.9 million, with a median of -$8.7 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 1185694.2% in 2021, then tumbled by 107594.94% in 2023.
  • Quarter analysis of 5 years shows Fulgent Genetics' Net Income towards Common Stockholders stood at $103.7 million in 2021, then crashed by 123.22% to -$24.1 million in 2022, then plummeted by 432.27% to -$128.1 million in 2023, then skyrocketed by 95.41% to -$5.9 million in 2024, then fell by 12.23% to -$6.6 million in 2025.
  • Its last three reported values are -$6.6 million in Q3 2025, -$19.0 million for Q2 2025, and -$11.5 million during Q1 2025.